home news forum careers events suppliers solutions markets expos directories catalogs resources advertise contacts
 
News Page

The news
and
beyond the news
Index of news sources
All Africa Asia/Pacific Europe Latin America Middle East North America
  Topics
  Species
Archives
News archive 1997-2008
 

BCD Bioscience receives research grant to create functional oligosaccharides


Davis, California, USA
October 29, 2019

BCD Bioscience (http://www.bcdbio.com; “BCD”), a carbohydrate-mediated solution provider, announces that it has been awarded a grant by the Bill & Melinda Gates Foundation to create functional oligosaccharides or glycan for human health and nutrition applications. Under the terms of this grant, BCD will produce the glycan pools by running its patent-pending digestion process on a range of high fiber natural materials. The glycans will be screened by BCD and other Gates Foundation collaborators in a range of microbiome, anti-inflammatory and immune modulation assays, to evaluate their potential to enhance nutrition and health.

“BCD is excited to deploy our novel approach to potentially address a range of the developing world’s needs,” said Dr. Steve Watkins, CEO of BCD. “Enteric diseases and malnutrition have a dramatic impact in low-resource geographies. Establishing a healthy microbiome by introducing specific glycans in the diet has the potential to support and enhance digestive health to impact length and quality of life.”

Though glycans have been produced and consumed for a number of years, the current number of commercially available glycans is limited. Given this, their functional utility and selectivity is also restricted. BCD has the unique capability to create, characterize and screen thousands of unique structures from nature that are not readily available for testing. With support from the Bill & Melinda Gates Foundation, BCD will be able to more quickly produce greater structural diversity for mining across a range of health-enhancing applications.

About BCD Bioscience

BCD Bioscience (formerly known as Calyxo Biosystems) catalogs the broadly untapped world of natural carbohydrate structures to efficiently create and commercialize novel prebiotics, synbiotics and immuno-modulatory therapies for human and animal health. A spin-out out of the University of California, Davis; the company was founded in early 2019 by professors Dr. Carlito Lebrilla, Dr. David Mills and Dr. Bruce German.

To learn more, visit www.bcdbio.com, or contact info@bcdbio.com.
 



More news from: BCD Bioscience


Website: http://www.bcdbio.com

Published: November 12, 2019

The news item on this page is copyright by the organization where it originated
Fair use notice

 
 
 
 
 
 
 
 
 
 
 
 

  Archive of the news section

 

 


Copyright @ 1992-2025 SeedQuest - All rights reserved